anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dexmethylphenidate hydrochloride tablets contains dexmethylphenidate hydrochloride, a CNS stimulant. Dexmethylphenidate hydrochloride is the d-threo enantiomer of racemic methylphenidate hydrochloride. Dexmethylphenidate hydrochloride tablets is available as 2.5 mg, 5 mg, and 10 mg strength tablets for oral administration.

Chemically, dexmethylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, (R, R’)- (+)-. Its molecular formula is C14H19NO2•HCl. Its structural formula is:

Note: * = asymmetric carbon centers

Dexmethylphenidate hydrochloride is a white to off-white powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77 g/mol.

Inactive ingredients:Dexmethylphenidate hydrochloride tablets also contains the following inert ingredients: lactose anhydrous, magnesium stearate, microcrystalline cellulose and pregelatinized starch. Additionally, 5 mg tablets contain D&C Yellow #10 aluminum lake; 2.5 mg tablets contains FD&C Blue #1 aluminum lake.
After debridement, the wound is cleaned and disinfected with ethacridine lactate solution, then covered and dressed with sterile gauze. The dressing is changed every other day. The treatment period is 4-8 weeks.
FIELD: pharmacy. SUBSTANCE: antioxidant taken among the group including alkylphenols, benzopyrane derivatives, sodium thiosulfate and amino acids is added to pranoprofen an aqueous solution. Mass ratio of indicated antioxidant and pranoprofen is 0.0002-5.0. By the second variant of method of stabilization of pranoprofen an aqueous solution of pranoprofen is sealed in package made of antioxidant-containing material. Antioxidant is alkylphenol. Mass ratio of indicated antioxidant and package material is 0.0001-0.005. By the third variant of method of stabilization of pranoprofen an aqueous solution of pranoprofen is placed under conditions of limited oxygen feeding. An aqueous solution of pranoprofen is ophthalmic drops or solution used for the nasal cavity spraying. Decomposition of pranoprofen in its aqueous solution is inhibited significantly. Pranoprofen becomes stable in light that provides prolonged storage of pranoprofen-base aqueous preparation. EFFECT: improved method of stabilization, prolonged storage, improved properties. 18 cl, 4 tbl, 12 ex
Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated with chidamide combined with azacitidine for four cycles. For patients with interim-PET evaluation of PR, another two cycles of chidamide combined with azacitidine will be continued, followed by the second PET-CT efficacy evaluation, and those who achieve CR receive consolidation therapy with ASCT or another six cycles of chidamide combined with azacitidine. Subsequently, cidarbenamide monotherapy was given as maintenance therapy for 12 months. Patients with second efficacy evaluation of PR or SD or PD withdrew from this study.
Aquaculturists use polyploid fish to maximize production albeit with some unintended consequences including compromised behaviors and physiological function. Given benefits of probiotic therapies (e.g., improved immune response, growth, and metabolism), we explored probiotic supplementation (mixture of Bifidobacterium, Lactobacillus, and Lactococcus), to overcome drawbacks. We first examined fish gut bacterial community composition using 16S metabarcoding (via principal coordinate analyses and PERMANOVA) and determined probiotics significantly impacted gut bacteria composition (p = 0.001). Secondly, we examined how a genomic disruptor (triploidy) and diet supplements (probiotics) impact gene transcription and behavioral profiles of hatchery-reared Chinook salmon (Oncorhynchus tshawytscha). Juveniles from four treatment groups (diploid-regular feed, diploid-probiotic feed, triploid-regular feed, and triploid-probiotic feed; n = 360) underwent behavioral assays to test activity, exploration, neophobia, predator evasion, aggression/sociality, behavioral sensitivity, and flexibility. In these fish, transcriptional profiles for genes associated with neural functions (neurogenesis/synaptic plasticity) and biomarkers for stress response and development (growth/appetite) were (i) examined across treatments and (ii) used to describe behavioral phenotypes via principal component analyses and general linear mixed models. Triploids exhibited a more active behavioral profile (p = 0.002), and those on a regular diet had greater Neuropeptide Y transcription (p = 0.02). A growth gene (early growth response protein 1, p = 0.02) and long-term neural development genes (neurogenic differentiation factor, p = 0.003 and synaptysomal-associated protein 25-a, p = 0.005) impacted activity and reactionary profiles, respectively. Overall, our probiotic treatment did not compensate for triploidy. Our research highlights novel applications of behavioral transcriptomics for identifying candidate genes and dynamic, mechanistic associations with complex behavioral repertoires.
NEW MATERIAL:A surface-active cyclodextrin derivative expressed by formula I [CD is cyclic oligoglucose residue left after excluding H of all non-glycoside hydroxyl group of (branched) cyclodextrin in which glucose is a cyclic oligoglucose bonded at a position of 1,4; n is number of non-glycoside hydroxyl group; B is a group binding to oxygen to which H of non-glycoside hydroxyl group is bound, H or formula II (A is substituted ethylene, etc.; M is H, alkali metal, alkyl, etc.)]. USE:A stabilizer for surfactant, medicine, etc., and sustained release agent. PREPARATION:For example, cyclodextrins are reacted with an alkenylcinnamic acid anhydride (e.g. n-decenylcinnamic acid anhydride) or alkylcinnamic anhydride in a solvent (e.g. dimethyl formamide) containing no water and alcohol to provide the compound expressed by formula I.
This invention provides a cytotoxin composition that inhibits mitochondrial respiration and causes cytostasis in cells, independent of nitric oxide. The invention comprises a conditioned supernatant derived from macrophage cell line (EA13.5) that inhibits mitochondrial respiration and causes cytostasis in cells. More particularly, the invention comprises a macrophage cytotoxin obtained from conditioned supernatant collected from cultured EA13.5 cell. This macrophage cytotoxin (1) inhibits mitochondrial respiration, (2) causes cytostasis independent of L-arginine derived nitric oxide, (3) is a weakly acidic (pH of about 7.5 to 8.0) glycoprotein (as determined by binding to lentil lectin sepharose). The invention also discloses a method for producing an L-arginine-derived nitric oxide-independent macrophage cytotoxin by culturing EA13.5 cells, adding IFN-η and lipopolysaccharide to trigger secretion of the macrophage cytotoxin into the conditioned supernatant, collecting the conditioned supernatant, and isolating the macrophage cytotoxin from the conditioned supernatant. Further disclosed by this invention is a method for producing a nitric oxide independent macrophage cytotoxin, that inhibits mitochondrial respiration independent of L-arginine, from cultured rodent macrophages.
Although treatments for myocardial infarction have advanced significantly, the global mortality due to ischemia and subsequent reperfusion injury remains high. Here, a platelet (PLT) membrane nanocarrier (PL720) that encapsulates L-arginine and FTY720 to facilitate the cascade-targeted delivery of these substances to the myocardial injury site and enable the controlled release of L-arginine and FTY720 is developed. Such an innovative approach shows enhanced cardioprotection through multiple target strategies involved in ischemia-reperfusion injury and late reperfusion inflammation. During the ischemia-reperfusion phase, PL720 targets and accumulates in damaged coronary arteries. PL720 rapidly releases L-arginine, stimulating endothelial cells to produce NO, thereby dilating blood vessels and promoting blood flow recovery, while FTY720's sustained release exerts anti-apoptotic effects. During the late reperfusion inflammatory phase, PL720 is captured by circulating inflammatory monocytes and transported into a deeper ischemic myocardial lesion. PL720 promotes macrophage polarization and accelerates the inflammatory repair. Furthermore, the issue of bradycardia associated with the clinical use of FTY720 is innovatively relieved. Therefore, PL720 is a vascular injury and inflammation dual targeting strategy, exhibiting significant potential for multi-targeted therapy and clinical translation for cardiac injury.
FIELD: biotechnology. SUBSTANCE: invention relates to library of peptides immobilized on solid-phase carrier which represents unordered library of unprotected peptides containing numerous solid-phase carriers wherein one unprotected peptide type is bound to each solid-phase carrier and all statistically possible subunit combinations are included. Preparation of library involves introduction of subunit combination into solid-phase carrier aliquot in such a way as to introduce only one protected subunit into each aliquot, after which subunit is covalently bound to all reactive groups of solid-phase carrier and blocking and protective are removed. For identification of peptide, an active molecule specifically linking to library peptides is added to form complex, which is separated and peptide sequence therein is determined. EFFECT: expanded properties in preparing a variety of amino acid combinations of unordered peptide library. 15 cl, 12 dwg, 4 tbl, 14 ex
Type 2 diabetes (T2D) is a major risk factor for heart failure (HF) and has elevated incidence among individuals with HF. Since genetics and HF can independently influence T2D, collider bias may occur when T2D (i.e., collider) is controlled for by design or analysis. Thus, we conducted a genome-wide association study (GWAS) of diabetes-related HF with correction for collider bias. We first performed a GWAS of HF to identify genetic instrumental variables (GIVs) for HF and to enable bidirectional Mendelian randomization (MR) analysis between T2D and HF. We identified 61 genomic loci, significantly associated with all-cause HF in 114,275 individuals with HF and over 1.5 million controls of European ancestry. Using a two-sample bidirectional MR approach with 59 and 82 GIVs for HF and T2D, respectively, we estimated that T2D increased HF risk (odds ratio [OR] 1.07, 95% confidence interval [CI] 1.04-1.10), while HF also increased T2D risk (OR 1.60, 95% CI 1.36-1.88). Then we performed a GWAS of diabetes-related HF corrected for collider bias due to the study design of index cases. After removing the spurious association of TCF7L2 locus due to collider bias, we identified two genome-wide significant loci close to PITX2 (chromosome 4) and CDKN2B-AS1 (chromosome 9) associated with diabetes-related HF in the Million Veteran Program and replicated the associations in the UK Biobank. Our MR findings provide strong evidence that HF increases T2D risk. As a result, collider bias leads to spurious genetic associations of diabetes-related HF, which can be effectively corrected to identify true positive loci.
Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand ('TRAIL') Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
OBJECTIVE: To determine the frequency of oral squamous cell carcinoma (OSCC) associated or not with oral potentially malignant disorders (OPMD), and the epidemiological profile and traditional risk factors in Latin America.
METHODS: A retrospective observational study was conducted in 17 Latin American centres. There were included cases of OSCC, analysing age, gender, OSCC and their association with previous OPMD. Clinicopathological variables were retrieved. The condition of sequential-OSCC versus OSCC-de novo (OSCC-dn) was analysed concerning the aforementioned variables. Quantitative variables were analysed using Student's t-test, and qualitative variables with chi-square.
RESULTS: In total, 2705 OSCC were included with a mean age of 62.8 years old. 55.8% were men. 53.75% of the patients were smokers and 38% were common drinkers. The lateral tongue border was the most affected site (24.65%). There were regional variations in OPMD, being leukoplakia the most frequent. Of the overall 2705 OSCC cases, 81.4% corresponded to OSCC-dn, while s-OSCC were 18.6%. Regarding lip vermillion SCC, 35.7% corresponded to de novo lip SCC and 64.3% were associated with previous OPMD.
CONCLUSIONS: In Latin America, OSCC-dn seems to be more frequent with regional variations of some clinical and histopathological features. Further prospective studies are needed to analyse this phenomenon.
The present discovery generally pertains to the formulation of therapeutic compounds to treat the symptoms of esophageal disorders. More specifically, the present discovery pertains to two 1-di-alkyl-phosphinoyl-alkanes (DIPA) called DIPA-1-8 and DIPA-1-9. These compounds are formulated as a shaped medicament and swallowed to suppress the symptoms of esophageal reflux and dyspepsia. The DIPA act by creating sensations of coolness and cold on the pharyngeal and esophageal lining. Some of the symptoms relieved include cough, chronic cough, heartburn, chest pain, bloat, belching, and dyspepsia. A preferred embodiment is DIPA-1-9 dissolved in a gel matrix. An aspect of the invention is to design the medicament to be intercepted, impeded, ensnarled, or trapped in the pharyngeal valleculae and pyriform sinuses before it passes down the esophagus. The goal is to prolong the transit time of the medicament, also herein sometimes call the Shaped-Gel, in the hypopharynx and esophagus, so the active ingredient has ample time to dissolve in saliva and reach receptors for cooling. By experiment, the ideal formulation of the Shaped-Gel was a flat rectangular or toroid shape, with a mass of 0.3 to 0.8 g. Flatness was defined as a pill with the shortest axis, preferentially 5 to 45% of the longest axis.
Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
The invention relates to a method for preparing a nanometer medicament carrier with extrusion and switch effects. A self-made triblock amphiphilic polymer is adopted as a surfactant and a macromolecular reversible addition-fragmentation chain transfer reagent for polymerization of microemulsion, a nanometer carrier with a core-shell structure is obtained by living polymerization of the microemulsion, and a pH responsive type nanometer medicament carrier is obtained by further hydrolysis. The nanometer carrier can be stored as lyophilized powder, and a core layer and a shell layer each have unique functions. The core layer is rapidly contracted from a swelling state at a tumor or inflammation part with an acidic pH value, thereby rapidly extruding an embedded medicament. A polyethylene glycol fragment of the shell layer makes nanoparticles invisible in an in-vivo circulation process, so that the in-vivo circulating half life of the medicament carrier is prolonged. A cationic polymer fragment of the shell layer is adsorbed onto the core layer under the action of static electricity in case of a neutral pH value to prevent the medicament from being released, and enters a stretched state along with disappearance of the action of the static electricity in case of an acidic pH value to facilitate release of the medicament, so that a switch function is realized. The nanometer medicament carrier has great application potential in the field of controlled release of medicaments, in particular on the aspect of chemotherapy of malignant tumors.
The present study was conducted to investigate the effects of Ocimum basilicum L. (OB) extract on learning and memory impairment in aged rats. Male rats were divided into the following experimental groups: Group 1 (control): including 2 months old rats, Group 2 (aged) including 2 years old rats, Groups 3-5 (aged-OB): including 2 years old rats received 50, 100, and 150 mg/kg OB for 8 weeks by oral gavage. Aging increased the delay to find the platform but, however, decreased the time spent in the target quadrant when tested by Morris water maze (MWM). Aging also reduced the latency to enter the dark chamber in the passive avoidance (PA) test compared to the control group. Moreover, interleukin-6 (IL-6) and malondialdehyde (MDA) levels were raised in the hippocampus and cortex of aged rats. In contrast, thiol levels and enzymatic activity of superoxide dismutase (SOD) and catalase (CAT) significantly reduced. In addition, aging significantly reduced BDNF expression. Finally, OB administration reversed the mentioned effects. The current research showed that OB administration improves learning/memory impairment induced by aging. It also found that this plant extract protects the brain tissues from oxidative damage and neuroinflammation.
Therapy with Fecal microbiota transplantation with SMT (Baclofen + AUD counselling). - Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4.
<P>PROBLEM TO BE SOLVED: To provide a solid cosmetic on which highly appealing characters or patterns can be formed.  <P>SOLUTION: The solid cosmetic has an adhesive layer formed in the shape of characters or patterns with an adhesive, a holding member 1 for holding the adhesive layer, and a cosmetic layer 2 formed by stacking a cosmetic material and solidified on one surface of the holding member so as to cover a part or the whole of the adhesive layer. The adhesive layer has one or more layers. When two or more adhesive layers are stacked, it is preferred that the adhesive be applied so as to overlap a part of one surface of the adhesive layer, or the adhesive be applied in a prescribed area which is smaller than the one surface. The adhesive is preferably polyvinylpyrrolidone.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The aim of this study is to compare the effectiveness of a CNS-directed treatment program versus a standard medical and physiotherapy care program on outcomes in participants with Frozen Shoulder (FS). It will consist of a randomized double-blind clinical trial (both participants and evaluators). The sample will consist of subjects with primary or idiopathic FS.

Once the sample is selected, participants will be randomly assigned to receive either a CNS-centered treatment program or a standard physiotherapy program. The CNS-centered treatment program will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week. On the other hand, subjects assigned to the standard physiotherapy group will receive a 10-session treatment program, such as the CNS-centered treatment group. This standard treatment will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. Physiotherapists will be instructed not to include interventions that were similar to those used in the group receiving the CNS-focused protocol (e.g. using mirrors or imagined movements) and to include a home program that involves a training load comparable to that in the other group. Adherence to both interventions will be monitored using an individual treatment diary where the time of day and duration of each clinic and home session will be recorded To evaluate the results of the interventions, the subjects will be assessed at the beginning, at the end of the treatment program (week 10) and at 3 and 6 months of follow-up.
TQB3558 tablets administered orally once. Then TQB3558 tablet administered orally, once daily in 28-day cycle after 4 days of first administration.
Acute appendicitis is one of the most common surgical emergencies in adult patients. The lifetime risk of developing acute appendicitis in the United States is 8.6% for males and 6.7% for females. For many decades, surgical appendicectomy is the gold standard of treatment of acute appendicitis. Appendicectomy could be performed in an open manner via a right lower abdominal incision, or more popular nowadays with the laparoscopic approach by placing three abdominal trocars. Earlier studies have identified high treatment success rate with both open and laparoscopic approaches, but adverse events were lower in laparoscopic group. Intra-abdominal abscesses were a potential concern with laparoscopic appendicectomy. In recent few years, antibiotics treatment for acute appendicitis has been a promising management option. By avoid the need of surgery and general anaesthesia, the non-operative approach was associated with a lower morbidity than the surgical approach. The major drawback of antibiotic treatment was the risk of failed primary treatment and subsequent recurrent appendicitis. A recent randomized controlled study demonstrated a primary clinical success treatment at index attack of 94.2%. 72.7% of the patients who received antibiotics alone did not require appendicectomy at 1-year follow-up. While antibiotics therapy could be a safe alternative to surgical therapy, many are still skeptical of the treatment due to the potential high recurrence rate.

Endoscopic therapy of acute appendicitis (Endoscopic retrograde appendicitis therapy, ERAT) was recently described recently in the literature. The technique involves a two-staged procedure with endoscopic plastic stent drainage of appendiceal orifice followed by stent and appendicolith retrieval. These were small case series conducted in China demonstrating technical feasibility and initial clinical success rate of this alternative approach. The technique has not been practiced in most centers across the world. The merit of endoscopic treatment lies in its potential to remove the appendicolith thereby reducing the recurrence rate. It could provide an invaluable treatment option that overcomes the drawback of high recurrence rate with antibiotics alone.

Given that the novel endoscopic technique has not been widely adopted, the investigators plan to conduct this pilot study to investigate the feasibility, technical and clinical success rate of endoscopic retrograde appendicitis therapy among adult patients with uncomplicated acute appendicitis.